Seeking Alpha

Bristol-Myers (BMY) is returning its share of global rights to blood thinner Plavix and blood...

Bristol-Myers (BMY) is returning its share of global rights to blood thinner Plavix and blood pressure treatment Avalide to Sanofi (SNY) following the loss of patent protection for the drugs, although the American firm will retain U.S. and Puerto Rico rights to Plavix. BMY will receive royalties until 2018 and then a $200M terminal payment, although it's paying $80M to Sanofi over supply disruption to Avalide in the U.S. in 2011. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector